PROVETOP

FITC-Labeled Human CD47 Protein

Catalog No: CD47-HP003

Species
Human
Expression System
HEK293
Tag
His
Activity
Activity verified

Product overview

Recombinant FITC-Labeled Human CD47 Protein is expressed in HEK293 cells with a His tag at the C-terminus. It contains amino acid residues Gln19-Pro139 (UniProt accession: Q08722-1).

Product Details

Molecular Aliases
CD47 glycoprotein; CD47 molecule; CD47; IAP; OA3; MER6
Protein Length
Gln19-Pro139
Expression System
HEK293
Theoretical Molecular Weight
The protein has a predicted MW of 14.5 kDa. Due to glycosylation, the protein migrates to 45-55 kDa based on Bis-Tris PAGE result.
Purity
> 95% as determined by Bis-Tris PAGE > 90% as determined by HPLC
Buffer / Formulation
Supplied as 0.22 μm filtered solution in PBS (pH 7.4).
State
Liquid
Storage Conditions
Valid for 6 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Data Display

Bis-Tris PAGE
CD47-HP003 Bis-Tris-PAGE-white result

FITC-Labeled Human CD47 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC
CD47-HP003 SEC-HPLC result

The purity of FITC-Labeled Human CD47 is greater than 90% as determined by SEC-HPLC.

ELISA
CD47-HP003 ELISA result

Immobilized FITC-Labeled Human CD47, His Tag at 1μg/ml (100μl/well) on the plate. Dose response curve for Human SIRP alpha, hFc Tag with the EC50 of 77.4ng/ml determined by ELISA (QC Test).

Background

CD47 (Cluster of Differentiation 47) also known as integrin associated protein (IAP) is a transmembrane protein that in humans is encoded by the CD47 gene. CD47 belongs to the immunoglobulin superfamily and partners with membrane integrins and also binds the ligands thrombospondin-1 (TSP-1) and signal-regulatory protein alpha (SIRPα).CD-47 acts as a don't eat me signal to macrophages of the immune system which has made it a potential therapeutic target in some cancers.

References

  1. Weiskopf K, Ring A M, Ho C C M, et al. Engineered SIRP? Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies[J]. Science, 2013, 341(6141):88-91.

Have questions about this product?

Our technical team can help with product selection, application questions and order support.

Contact Technical Support